{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:35:54Z","timestamp":1788104154267,"version":"build-2803163510"},"reference-count":109,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["5R01AR056019 -13"],"award-info":[{"award-number":["5R01AR056019 -13"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhandsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Hand Surgery"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jhsa.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T20:12:39Z","timestamp":1679083959000},"page":"810-821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-1931","authenticated-orcid":false,"given":"Alex G.","family":"Lambi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven N.","family":"Popoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prosper","family":"Benhaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Barbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhsa.2023.02.003_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249687","article-title":"Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action","volume":"16","author":"Karatzas","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jhsa.2023.02.003_bib2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbadis.2012.12.007","article-title":"Strategies for anti-fibrotic therapies","volume":"1832","author":"Rosenbloom","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhsa.2023.02.003_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/biom11081095","article-title":"Myofibroblasts: function, formation, and scope of molecular therapies for skin fibrosis","volume":"11","author":"Tai","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jhsa.2023.02.003_bib4","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/SAP.0000000000001607","article-title":"Dupuytren\u2019s contracture: an evidence based review","volume":"81","author":"Mella","year":"2018","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1142\/S0218810415500264","article-title":"Critical angles of deformity in Dupuytren\u2019s contracture of the little and ring fingers","volume":"20","author":"Raymond","year":"2015","journal-title":"Hand Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib6","doi-asserted-by":"crossref","first-page":"240e","DOI":"10.1097\/PRS.0000000000002857","article-title":"Evidence-based medicine: options for Dupuytren\u2019s contracture: incise, excise, and dissolve","volume":"139","author":"Denkler","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrrheum.2010.180","article-title":"Scientific understanding and clinical management of Dupuytren disease","volume":"6","author":"Shih","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2106\/00004623-195941040-00008","article-title":"Dupuytren\u2019s contracture; a new concept of the pathogenesis correlated with surgical management","volume":"41-A","author":"Luck","year":"1959","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.hcl.2018.03.001","article-title":"The basic science of Dupuytren disease","volume":"34","author":"Zhang","year":"2018","journal-title":"Hand Clin"},{"key":"10.1016\/j.jhsa.2023.02.003_bib10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jclinepi.2003.11.015","article-title":"A\u00a0prospective study linked both alcohol and tobacco to Dupuytren\u2019s disease","volume":"57","author":"Godtfredsen","year":"2004","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/J.JHSE.2005.02.002","article-title":"An assessment of the effects of exposure to vibration, smoking, alcohol and diabetes on the prevalence of Dupuytren\u2019s disease in 97,537 miners","volume":"32","author":"Burke","year":"2007","journal-title":"J\u00a0Hand Surg Eur Vol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1302\/0301-620X.79B2.0790206","article-title":"Smoking, alcohol and the risk of Dupuytren\u2019s contracture","volume":"79","author":"Burge","year":"1997","journal-title":"J\u00a0Bone Joint Surg Br"},{"key":"10.1016\/j.jhsa.2023.02.003_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/(SICI)1097-0274(199605)29:5<521::AID-AJIM12>3.0.CO;2-2","article-title":"Can Dupuytren\u2019s contracture be work-related?: review of the evidence","volume":"29","author":"Liss","year":"1996","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.jhsa.2023.02.003_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0895-4356(99)00145-6","article-title":"Epidemiology of Dupuytren\u2019s disease: clinical, serological, and social assessment. The Reykjavik Study","volume":"53","author":"Gudmundsson","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1302\/0301-620X.66B3.6725338","article-title":"Diabetes mellitus in the aetiology of Dupuytren\u2019s disease","volume":"66","author":"Noble","year":"1984","journal-title":"J\u00a0Bone Joint Surg Br"},{"key":"10.1016\/j.jhsa.2023.02.003_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11552-010-9306-4","article-title":"Prevalence, incidence, and treatments of Dupuytren\u2019s disease in the United States: results from a population-based study","volume":"6","author":"Dibenedetti","year":"2011","journal-title":"Hand (N Y)"},{"key":"10.1016\/j.jhsa.2023.02.003_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94025-7","article-title":"Metabolic factors and the risk of Dupuytren\u2019s disease: data from 30,000 individuals followed for over 20 years","volume":"11","author":"Rydberg","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhsa.2023.02.003_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF02537234","article-title":"Lipid composition and de novo lipid biosynthesis of human palmar fat in Dupuytren\u2019s disease","volume":"18","author":"Rabinowitz","year":"1983","journal-title":"Lipids"},{"key":"10.1016\/j.jhsa.2023.02.003_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0266-7681(93)90123-W","article-title":"Prevalence of Dupuytren\u2019s contracture and its correlation with degenerative changes of the hands and feet and with criteria of general health","volume":"18","author":"Bergenudd","year":"1993","journal-title":"J\u00a0Hand Surg Br"},{"key":"10.1016\/j.jhsa.2023.02.003_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11552-009-9164-0","article-title":"Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren\u2019s disease nodule in comparison to control tissue","volume":"4","author":"Shih","year":"2009","journal-title":"Hand (N Y)"},{"key":"10.1016\/j.jhsa.2023.02.003_bib21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/sj.jid.5700613","article-title":"Formation and function of the myofibroblast during tissue repair","volume":"127","author":"Hinz","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.2106\/00004623-198769090-00013","article-title":"Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease","volume":"69","author":"Tomasek","year":"1987","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrm809","article-title":"Myofibroblasts and mechano-regulation of connective tissue remodelling","volume":"3","author":"Tomasek","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib24","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1083\/jcb.98.6.2091","article-title":"In\u00a0vivo co-distribution of fibronectin and actin fibers in granulation tissue: immunofluorescence and electron microscope studies of the fibronexus at the myofibroblast surface","volume":"98","author":"Singer","year":"1984","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.12.1.463","article-title":"Focal adhesions, contractility, and signaling","volume":"12","author":"Burridge","year":"1996","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib26","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1242\/jcs.114.18.3285","article-title":"Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors","volume":"114","author":"Dugina","year":"2001","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.jhsa.2023.02.003_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.mehy.2011.11.023","article-title":"Concurrent inhibition of TGF-beta and mitogen driven signaling cascades in Dupuytren\u2019s disease - non-surgical treatment strategies from a signaling point of view","volume":"78","author":"Krause","year":"2012","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jhsa.2023.02.003_bib28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/BF02389692","article-title":"TGF beta and bFGF synthesis and localization in Dupuytren\u2019s disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin","volume":"27","author":"Berndt","year":"1995","journal-title":"Histochem J"},{"key":"10.1016\/j.jhsa.2023.02.003_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jcp.46.5.425","article-title":"Abnormal growth factor and cytokine expression in Dupuytren\u2019s contracture","volume":"46","author":"Baird","year":"1993","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0363-5023(96)80102-X","article-title":"The role of transforming growth factor beta in Dupuytren\u2019s disease","volume":"21","author":"Badalamente","year":"1996","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0266-7681(03)00135-9","article-title":"The different characteristics of Dupuytren\u2019s disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1","volume":"28","author":"Bisson","year":"2003","journal-title":"J\u00a0Hand Surg Br"},{"key":"10.1016\/j.jhsa.2023.02.003_bib32","doi-asserted-by":"crossref","first-page":"E928","DOI":"10.1073\/pnas.1301100110","article-title":"Unraveling the signaling pathways promoting fibrosis in Dupuytren\u2019s disease reveals TNF as a therapeutic target","volume":"110","author":"Verjee","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhsa.2023.02.003_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1755-1536-4-14","article-title":"Elevated transforming growth factor beta and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren\u2019s disease fibroblasts","volume":"4","author":"Krause","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.jhsa.2023.02.003_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2474-5-41","article-title":"Enhanced Dupuytren\u2019s disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2","volume":"5","author":"Tse","year":"2004","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jhsa.2023.02.003_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1755-8794-5-15","article-title":"Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren\u2019s contracture","volume":"5","author":"Satish","year":"2012","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jhsa.2023.02.003_bib36","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1039\/C2MB25173F","article-title":"Dupuytren\u2019s disease metabolite analyses reveals alterations following initial short-term fibroblast culturing","volume":"8","author":"Rehman","year":"2012","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.jhsa.2023.02.003_bib37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jcp.22167","article-title":"Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren\u2019s nodular cells","volume":"224","author":"Verjee","year":"2010","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/thx.2004.040022","article-title":"Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias","volume":"62","author":"Gotway","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jhsa.2023.02.003_bib39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41598-020-78747-8","article-title":"Non-invasive assessment of skeletal muscle fibrosis in mice using nuclear magnetic resonance imaging and ultrasound shear wave elastography","volume":"11","author":"Martins-Bach","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhsa.2023.02.003_bib40","doi-asserted-by":"crossref","first-page":"822e","DOI":"10.1097\/PRS.0000000000000603","article-title":"Minimally invasive options in Dupuytren\u2019s contracture: aponeurotomy, enzymes, stretching, and fat grafting","volume":"134","author":"Murphy","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.hcl.2018.03.004","article-title":"Development of collagenase treatment for Dupuytren disease","volume":"34","author":"Badalamente","year":"2018","journal-title":"Hand Clin"},{"key":"10.1016\/j.jhsa.2023.02.003_bib42","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11552-012-9424-2","article-title":"What were the adverse events for Dupuytren\u2019s patients treated with Xiaflex who had contractures less than 20\u00b0?","volume":"7","author":"Freshwater","year":"2012","journal-title":"Hand"},{"key":"10.1016\/j.jhsa.2023.02.003_bib43","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/1753193418786947","article-title":"Three-year recurrence of Dupuytren\u2019s contracture after needle fasciotomy and collagenase injection: a two-centre randomized controlled trial","volume":"43","author":"Scherman","year":"2018","journal-title":"J\u00a0Hand Surg Eur Vol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhsa.2017.03.003","article-title":"Injectable collagenase versus percutaneous needle fasciotomy for Dupuytren contracture in proximal interphalangeal joints: A randomized controlled trial","volume":"42","author":"Skov","year":"2017","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib45","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/GOX.0000000000000249","article-title":"The rationale for treating the nodule in Dupuytren\u2019s disease","volume":"2","author":"Ketchum","year":"2014","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.jhsa.2023.02.003_bib46","first-page":"421","article-title":"Hydrocortisone acetate in the treatment of Dupuytren\u2019s contraction and allied conditions","volume":"109","author":"Zachariae","year":"1955","journal-title":"Acta Chir Scand"},{"key":"10.1016\/j.jhsa.2023.02.003_bib47","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1053\/jhsu.2000.18493","article-title":"The injection of nodules of Dupuytren\u2019s disease with triamcinolone acetonide","volume":"25","author":"Ketchum","year":"2000","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib48","first-page":"863","article-title":"[Treatment of Dupuytren\u2019s disease by local injections of hydrocortisone]","volume":"20","author":"Coste","year":"1953","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.jhsa.2023.02.003_bib49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1054\/jhsb.2001.0742","article-title":"The effect of steroids on Dupuytren\u2019s disease: role of programmed cell death","volume":"27","author":"Meek","year":"2002","journal-title":"J\u00a0Hand Surg Br"},{"key":"10.1016\/j.jhsa.2023.02.003_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00006534-196707000-00016","article-title":"The degradation of mature collagen: a laboratory study","volume":"40","author":"Ketchum","year":"1967","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib51","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jhsa.2012.04.026","article-title":"Steroid injection and needle aponeurotomy for Dupuytren contracture: a randomized, controlled study","volume":"37","author":"McMillan","year":"2012","journal-title":"J\u00a0Hand Surg Am"},{"issue":"Suppl 1","key":"10.1016\/j.jhsa.2023.02.003_bib99","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/DSS.0000000000000819","article-title":"Keloids and hypertrophic scars: pathophysiology, classification, and treatment","volume":"43","author":"Berman","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhsa.2023.02.003_bib101","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/jor.24441","article-title":"Inhibition of COX-2 pathway as a potential prophylaxis against arthrofibrogenesis in a rabbit model of joint contracture","volume":"37","author":"Salib","year":"2019","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.jhsa.2023.02.003_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101774","article-title":"Silencing COX-2 blocks PDK1\/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy","volume":"38","author":"Chen","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib103","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons. Mechanisms of action and clinical applications","volume":"266","author":"Baron","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.jhsa.2023.02.003_bib54","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/00006534-199405000-00018","article-title":"Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren\u2019s disease: an open pilot study","volume":"93","author":"Pittet","year":"1994","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib55","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/jhsu.1999.0578","article-title":"The effect of interferon-alpha2b on an in\u00a0vitro model Dupuytren\u2019s contracture","volume":"24","author":"Sanders","year":"1999","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib104","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.hcl.2018.03.005","article-title":"Alternative and adjunctive treatments for Dupuytren disease","volume":"34","author":"Werker","year":"2018","journal-title":"Hand Clin"},{"key":"10.1016\/j.jhsa.2023.02.003_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1297-3203(00)73455-X","article-title":"The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation","volume":"19","author":"Jemec","year":"2000","journal-title":"Chir Main"},{"key":"10.1016\/j.jhsa.2023.02.003_bib57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhsb.2003.08.002","article-title":"A\u00a0prospective randomised clinical trial of the intra-operative use of 5-fluorouracil on the outcome of Dupuytren\u2019s disease","volume":"29","author":"Bulstrode","year":"2004","journal-title":"J\u00a0Hand Surg Br"},{"key":"10.1016\/j.jhsa.2023.02.003_bib105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(73)91248-8","article-title":"Colchicine and the treatment of liver cirrhosis","volume":"1","author":"Rojkind","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jhsa.2023.02.003_bib106","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1073\/pnas.69.4.892","article-title":"Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs","volume":"69","author":"Diegelmann","year":"1972","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhsa.2023.02.003_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","article-title":"Is colchicine effective in Peyronie\u2019s disease? A pilot study","volume":"44","author":"Akkus","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.jhsa.2023.02.003_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102241","article-title":"Emerging strategies for treating gout","volume":"65","author":"Huddleston","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib108","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27235","article-title":"Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity","volume":"61","author":"Guy","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhsa.2023.02.003_bib62","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/bmj.1.4772.1328","article-title":"Dupuytren\u2019s contracture treated with vitamin E","volume":"1","author":"Richards","year":"1952","journal-title":"Br Med J"},{"key":"10.1016\/j.jhsa.2023.02.003_bib63","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/archsurg.1951.01250040840013","article-title":"Tocopherols in treatment of primary fibrositis; including Dupuytren\u2019s contracture, periarthritis of the shoulders, and Peyronie\u2019s disease","volume":"63","author":"Steinberg","year":"1951","journal-title":"AMA Arch Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib60","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bcp.2005.07.001","article-title":"N-acetyl-L-cysteine suppresses TGF-beta signaling at distinct molecular steps: the biochemical and biological efficacy of a multifunctional, antifibrotic drug","volume":"70","author":"Meurer","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1582-4934.2006.tb00297.x","article-title":"N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren\u2019s disease by blunting TGF-beta signalling","volume":"10","author":"Kopp","year":"2006","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jhsa.2023.02.003_bib109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)00446-6","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jhsa.2023.02.003_bib65","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.1523-1755.2004.00901.x","article-title":"Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect","volume":"66","author":"Yu","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhsa.2023.02.003_bib66","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/01.prs.0000287381.93729.e2","article-title":"The effects of angiotensin-converting-enzyme inhibitors on the fibrous envelope around mammary implants","volume":"120","author":"Zimman","year":"2007","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/2000656X.2017.1319846","article-title":"Angiotensin receptors in Dupuytren\u2019s disease: a target for pharmacological treatment?","volume":"52","author":"Stephen","year":"2018","journal-title":"J\u00a0Plast Surg Hand Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archsurg.1994.01420250119015","article-title":"The response of burn scars to intralesional verapamil. Report of five cases","volume":"129","author":"Lee","year":"1994","journal-title":"Arch Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib69","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0363-5023(96)80317-0","article-title":"Pharmacologic regulation of Dupuytren\u2019s fibroblast contraction in\u00a0vitro","volume":"21","author":"Rayan","year":"1996","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie\u2019s disease with PDE5 inhibitors: an antifibrotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2007.06.036","article-title":"Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase","volume":"572","author":"Dunkern","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib72","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","article-title":"Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease","volume":"97","author":"Ferrini","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.jhsa.2023.02.003_bib74","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/niox.2001.0421","article-title":"Antifibrotic role of inducible nitric oxide synthase","volume":"6","author":"Ferrini","year":"2002","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.jhsa.2023.02.003_bib75","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1089-8603(02)00124-6","article-title":"Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie\u2019s fibrotic plaque and in its rat model","volume":"7","author":"Vernet","year":"2002","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.jhsa.2023.02.003_bib77","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000637-199805000-00008","article-title":"Tamoxifen downregulates TGF-beta production in keloid fibroblasts","volume":"40","author":"Chau","year":"1998","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib76","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/jsre.2001.6350","article-title":"Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren\u2019s affected palmar fascia","volume":"103","author":"Kuhn","year":"2002","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jhsa.2023.02.003_bib79","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2106\/JBJS.L.01623","article-title":"High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for Dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial","volume":"96","author":"Degreef","year":"2014","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib78","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","article-title":"Clinical and biomarker predictors of side effects from tamoxifen","volume":"132","author":"Lorizio","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jhsa.2023.02.003_bib80","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/ncomms3192","article-title":"Metformin improves healthspan and lifespan in mice","volume":"4","author":"Martin-Montalvo","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhsa.2023.02.003_bib81","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/0194599813513880","article-title":"Metformin reduces TGF-beta1-induced extracellular matrix production in nasal polyp-derived fibroblasts","volume":"150","author":"Park","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112930","article-title":"A\u00a0role for metformin in the treatment of Dupuytren disease?","volume":"150","author":"Baeri","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jhsa.2023.02.003_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12891-016-1200-y","article-title":"Systematic review of non-surgical treatments for early Dupuytren\u2019s disease","volume":"17","author":"Ball","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jhsa.2023.02.003_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/02844310151032691","article-title":"Acute postoperative swelling after hand surgery: an exploratory, double-blind, randomised study with paracetamol, naproxen, and placebo","volume":"35","author":"Husby","year":"2001","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"key":"10.1016\/j.jhsa.2023.02.003_bib59","doi-asserted-by":"crossref","first-page":"C1640","DOI":"10.1152\/ajpcell.1998.275.6.C1640","article-title":"Activation of the JAK-STAT pathway by reactive oxygen species","volume":"275","author":"Simon","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib61","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/bmj.2.4641.1382","article-title":"Treatment of Dupuytren\u2019s contracture with vitamin E","volume":"2","author":"Thomson","year":"1949","journal-title":"Br Med J"},{"key":"10.1016\/j.jhsa.2023.02.003_bib73","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10753-014-9841-1","article-title":"Protective and therapeutic effect of molsidomine on bleomycin-induced lung fibrosis in rats","volume":"37","author":"Kilic","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.jhsa.2023.02.003_bib83","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ebiom.2018.06.022","article-title":"Anti-tumour necrosis factor therapy for Dupuytren\u2019s disease: A randomised dose response proof of concept phase 2a clinical trial","volume":"33","author":"Nanchahal","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhsa.2023.02.003_bib84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.12688\/wellcomeopenres.11466.1","volume":"2","author":"Nanchahal","year":"2017","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jhsa.2023.02.003_bib85","doi-asserted-by":"crossref","first-page":"E407","DOI":"10.1016\/S2665-9913(22)00093-5","article-title":"Anti-tumour necrosis factor therapy for early-stage Dupuytren\u2019s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"4","author":"Nanchahal","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib86","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhsa.2023.02.003_bib87","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0363-5023(92)90415-L","article-title":"Basic fibroblast growth factor in cells derived from Dupuytren\u2019s contracture: synthesis, presence, and implications for treatment of the disease","volume":"17","author":"Lappi","year":"1992","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.jhsa.2023.02.003_bib88","first-page":"S195","article-title":"Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape","volume":"25","author":"Glassberg","year":"2019","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jhsa.2023.02.003_bib89","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhsa.2023.02.003_bib90","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12891-016-1326-y","article-title":"Anti-fibrotic action of pirfenidone in Dupuytren\u2019s disease-derived fibroblasts","volume":"17","author":"Zhou","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jhsa.2023.02.003_bib91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12891-019-2486-3","article-title":"Investigating the effects of pirfenidone on TGF-beta1 stimulated non-SMAD signaling pathways in Dupuytren\u2019s disease -derived fibroblasts","volume":"20","author":"Zhou","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jhsa.2023.02.003_bib92","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/10837450.2022.2038201","article-title":"Pirfenidone as a potential antifibrotic injectable for Dupuytren\u2019s disease","volume":"27","author":"Panigrahi","year":"2022","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.jhsa.2023.02.003_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020318","article-title":"Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: why IL-6?","volume":"10","author":"Cardoneanu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhsa.2023.02.003_bib94","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jhsa.2023.02.003_bib96","first-page":"322","article-title":"[Expression of various monoclonal antibodies in nodules and band stage in Dupuytren\u2019s disease]","volume":"28","author":"Brenner","year":"1996","journal-title":"Handchir Mikrochir Plast Chir"},{"key":"10.1016\/j.jhsa.2023.02.003_bib97","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0072-968X(79)80045-5","article-title":"Collagen types and anticollagen-antibodies in Dupuytren\u2019s disease","volume":"11","author":"Menzel","year":"1979","journal-title":"Hand"},{"key":"10.1016\/j.jhsa.2023.02.003_bib98","first-page":"58","article-title":"Antibodies to collagen types I\u2013VI in Dupuytren\u2019s contracture","volume":"11","author":"Pereira","year":"1986","journal-title":"J\u00a0Hand Surg Br"},{"key":"10.1016\/j.jhsa.2023.02.003_bib95","series-title":"Rituxan (rituximab) [package insert]","first-page":"1","year":"2021"}],"container-title":["The Journal of Hand Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0363502323000709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0363502323000709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:59:58Z","timestamp":1778749198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0363502323000709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":109,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0363502323000709"],"URL":"https:\/\/doi.org\/10.1016\/j.jhsa.2023.02.003","relation":{},"ISSN":["0363-5023"],"issn-type":[{"value":"0363-5023","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Hand Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhsa.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Society for Surgery of the Hand. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}